Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)

CompletedOBSERVATIONAL
Enrollment

153

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Glioblastoma
Trial Locations (19)

10032

Columbia University Medical Center, New York

10467

Montefiore Medical Center, The Bronx

11794

SUNY Stony Brook, Stony Brook

14642

University of Rochester Medical Center, Rochester

15261

University of Pittsburgh Medical Center, Pittsburgh

33136

University of Miami, Miami

35294

University of Alabama at Birmingham, Birmingham

37235

Vanderbilt University, Nashville

43210

Ohio State University, Columbus

45219

University of Cincinnati, Cincinnati

60208

Northwestern University, Chicago

63110

Washington University Medical School, St Louis

66160

University of Kansas Medical Center, Kansas City

75390

University of Texas Southwestern, Dallas

84112

University of Utah, Salt Lake City

95817

UC Davis, Sacramento

97239

Oregon Health & Science University, Portland

98122

Swedish Neuroscience Institute, Seattle

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

NeuroNEXT Network

OTHER

lead

University of Iowa

OTHER

NCT02997423 - Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM) | Biotech Hunter | Biotech Hunter